Business Wire

WORLD-GOLD-COUNCIL

4.5.2022 09:02:10 CEST | Business Wire | Press release

Share
aXedras Group AG Completes Series B Funding with Investment from The World Gold Council

aXedras Group AG (aXedras) announces it has concluded its Series B funding round, including a strategic investment from the World Gold Council (WGC) who will be represented on the Board of Directors by David Tait, CEO of WGC. The aXedras team is excited to have reached this latest milestone and will use this round of funding to move the business into a growth and global scaling phase.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005013/en/

aXedras uses blockchain- / distributed ledger technology to develop and implement a secure, confidential, digital supply chain solution for the precious metals industry, and to immutably document gold from the mine to the end-user.

Urs Röösli, Chief Executive Officer, aXedras commented:

“We are excited to partner with WGC and look forward to expanding on the work we have already done. Our Bullion Integrity Ledger™ provides investors, consumers and all market participants with provenance, integrity and chain of custody credentials. This is a critical step forward for the gold market in its digital transformation; it will help to keep gold relevant for 21st century investors.

“We are participating in the WGC and London Bullion Market Association (LBMA) Gold Bar Integrity Programme pilot to demonstrate how our proven technology ensures the integrity of gold by effectively digitalizing the global gold supply chain.”

David Tait, Chief Executive Officer, World Gold Council commented:

“The WGC recognises that initiatives like the Gold Bar Integrity Programme require industry-wide collaboration but also significant funding to ensure success. This project is essential to improve market infrastructure and that is why we’ve invested in aXedras. We have committed to return any and all commercial revenue earned from this investment, back into the industry, for the benefit and positive development of the global gold market.”

The Gold Bar Integrity Programme, which is now underway, has brought together representatives from the entire gold supply chain. This transformative project is the first step towards a digital industry standard and a more aligned gold industry, enabling it to work together for a more accessible and transparent market. aXedras’ solution, the Bullion Integrity Ledger™ is already being used by major gold refiners and logistics companies, and as a part of the Gold Bar Integrity Programme, the company will now expand this work to pilot participants.

ENDS

Notes to editors

aXedras:

aXedras provides a secure digital supply chain solution serving the global precious metal ecosystem. As an independent Swiss IT solution provider, aXedras’ objective is to take the precious metal industry to the next level of digitalization. The DLT/blockchain-based Bullion Integrity Ledger™ enables transparency of provenance data (ESG*-proof) and chain of custody in real time. It is a member-based network for peer-to-peer interaction between stakeholders, thus grants trusted and immutable data. The integrity of the product is guaranteed from suppliers, refiners, transporters, vaults, banks, watch & jeweller manufacturers to the end consumer.

The Bullion Integrity Ledger™ ensures the unique combination of efficiency, integrity, traceability and confidentiality of data and business transactions.

aXedras was founded in 2018 and is headquartered in Zug, Switzerland.

Learn more at www.axedras.com
Video: aXedras - Connecting and Digitalizing the Precious Metal Industry – YouTube
*Environmental, Social & Governance (ESG) criteria

World Gold Council:

We’re the global experts on gold.

Leveraging our broad knowledge and experience, we work to improve understanding of the gold market and underscore gold’s value to individuals, investors, and the world at large.

Collaboration is the cornerstone of our approach. We’re an association whose members are the world’s most forward-thinking gold mining companies. Combining the insights of our members and other industry partners, we seek to unlock gold’s evolving role as a catalyst for advancements that meet societal needs.

We develop standards, expand access to gold, and tackle barriers to adoption to stimulate demand and support a vibrant and sustainable future for the gold market. From our offices in Beijing, London, Mumbai, New York, Shanghai, and Singapore, we deliver positive impact worldwide.

You can follow the World Gold Council on Twitter at @goldcouncil and like on Facebook.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye